Miranda, RN, Khoury, JD, Medeiros, LJ. Atlas of Lymph Node Pathology. Springer, 2013.
Longmore, M, Wilkinson, I, Baldwin, A, Wallin, E.
Oxford Handbook of Clinical Medicine, 9th edn.
Oxford University Press, 2014.
Shenoy, P, Maggioncalda, A, Malik, N, Flowers, CR. Incidence patterns and outcomes for Hodgkin lymphoma patients in the United States. Adv Hematol
2011; 2011: .
Kuderer, NM, Dale, DC, Crawford, J, Cosler, LE, Lyman, GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer
2006; 106: 2258–6.
Meltzer, HY. Treatment-resistant schizophrenia – the role of clozapine. Curr Med Res Opin
1997; 14: 1–20.
National Institute for Health and Clinical Excellence. Psychosis and Schizophrenia in Adults: Treatment and Management (Clinical Guideline 178). NICE, 2014.
Taylor, D, Paton, C, Kapur, S.
The Maudsley Prescribing Guidelines in Psychiatry, 11th edn.
John Wiley & Sons, 2012.
Farooq, S, Taylor, M.
Clozapine: dangerous orphan or neglected friend?
Br J Psychiatry
2011; 198: 247–9.
Joint Formulary Committee. British National Formulary, 66th edn (September 2013–March 2014). British Medical Association and Royal Pharmaceutical Society of Great Britain, 2013.
Munro, J, O'Sullivan, D, Andrews, C, Arana, A, Mortimer, A, Kerwin, R.
Active monitoring of 12760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry
1999; 175: 576–80.
Huguet, G, Lillo-Le Louet, A, Darnige, L, Loo, H, Krebs, MO. Clozapine rechallenge in resistant schizophrenia disorder affecting ‘super sensitive’ patients, after neutropenia under clozapine: a case report [French]. Encephale
2013; 39: 42–8.
Taylor, DM, Young, C, Paton, C.
Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry
2003; 64: 30–4.
Mendelowitz, AJ, Gerson, SL, Alvir, JMJ, Lieberman, JA. Clozapine-induced agranulocytosis: risk factors, monitoring and management. CNS Drugs
1995; 4: 412–21.
McKenna, RC, Bailey, L, Haake, J, Desai, PN, Prasad, BR. Clozapine and chemotherapy. Hosp Comm Psychiatry
1994; 45: 831.
Sasieni, PD, Shelton, J, Ormiston-Smith, N, Thomson, CS, Silcocks, PB. What is the lifetime risk of developing cancer? The effect of adjusting for multiple primaries. Br J Cancer
2011; 105: 460–5.
Van Os, J, Kapur, S.
2009; 374: 635–45.
Clozapine therapy during cancer treatment. Am J Psychiatry
2004; 161: 175.
Hundertmark, J, Campbell, P.
Reintroduction of clozapine after diagnosis of lymphoma [letter]. Br J Psychiatry
2001; 178: 576.
Rosenberg, I, Mekinulov, B, Cohen, LJ, Galynker, I.
Restarting clozapine treatment during ablation chemotherapy and stem cell transplant for Hodgkin's lymphoma. Am J Psychiatry
2007; 164: 1438–9.
Munshi, T, Mazhar, M, Hassan, T.
Clozapine reinitiation following a ‘red result’ secondary to chemotherapy. Neuropsychiatr Dis Treat
2013; 9: 1267–71.
Alhmoud, N, Awwad, M, Jumaian, A, Shunaigat, W.
Hodgkin's lymphoma in a patient with resistant schizophrenia on clozapine therapy. JRMS
2007; 14: 61–3.
Patel, NC, Dorson, PG, Bettinger, TL. Sudden late onset of clozapine-induced agranulocytosis. Ann Pharmacother
2002; 36: 1012–15.
Cohen, D, Monden, M.
White blood cell monitoring during long-term clozapine treatment. Am J Psychiatry
2013; 170: 366–9.
Kutscher, EC, Robbins, GP, Kennedy, WK, Zebb, K, Stanley, M, Carnahan, RM. Clozapine-induced leukopenia successfully treated with lithium. Am J Health Syst Pharm
2007; 64: 2027–31.